Reduced healthcare utilization following successful hepatitis C virus treatment in HIV-co-infected patients with mild liver disease

Summary New direct‐acting antivirals (DAA) for hepatitis C virus (HCV) infection have achieved high cure rates in many patient groups previously considered difficult‐to‐treat, including those HIV/HCV co‐infected. The high price of these medications is likely to limit access to treatment, at least in...

Ausführliche Beschreibung